Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. Sun Appears Cheap Even After Receiving Nod from Competition Commission of India for Ranbaxy Merger

    Commentary

    Thu, 11 Dec 2014

    Sun Pharmaceuticals Industries and Ranbaxy , came through earlier this week ..... positive on the merger, as we believe Ranbaxy 's OTC and specialty drugs portfolio ..... are also present in the acquired Ranbaxy business. We believe the stock is

  2. UPDATE 1-India's regulator clears Sun Pharma- Ranbaxy deal

    Headlines

    Mon, 8 Dec 2014

    (Adds details from CCI order, comments from Sun and Ranbaxy , background)

  3. India's antitrust regulator clears Sun Pharma- Ranbaxy deal

    Headlines

    Mon, 8 Dec 2014

    MUMBAI, Dec 8 (Reuters) - India's antitrust regulator said on Monday it has approved generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd , subject to the companies divesting seven products.

  4. AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

    Headlines

    Fri, 5 Dec 2014

    Dec 5 (Reuters) - A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium...

  5. UPDATE 1- Ranbaxy says Europe bars imports from antibiotic injectables unit

    Headlines

    Thu, 4 Dec 2014

    * Ranbaxy says sees no significant impact on business (Recasts with statements from Ranbaxy and European regulator, adds details)

  6. Germany bars antibiotic drug from Ranbaxy's central India plant

    Headlines

    Wed, 3 Dec 2014

    MUMBAI, Dec 3 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd has been barred by from exporting the antibiotic cephalosporin to Germany from its plant in central India for not complying with standard manufacturing practices.

  7. UPDATE 1-U.S. court denies Ranbaxy's bid to block launch of rival generics

    Headlines

    Thu, 20 Nov 2014

    (Adds Endo's launch of generic Valcyte and Dr. Reddy's comment)

  8. U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

    Headlines

    Thu, 20 Nov 2014

    Nov 20 (Reuters) - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

  9. UPDATE 1- Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

    Headlines

    Tue, 18 Nov 2014

    * Ranbaxy alleges FDA's move violated constitutional rights

  10. Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

    Headlines

    Tue, 18 Nov 2014

    MUMBAI, Nov 18 (Reuters) - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

« Prev1234Next »
Content Partners